The Role of Eosinophils in Immunotherapy
- 7 January 2020
- journal article
- review article
- Published by Springer Nature in Current Allergy and Asthma Reports
- Vol. 20 (1) , 1-8
Abstract
Purpose of Review The purpose of this review is to provide a brief discussion on the differential diagnosis for peripheral eosinophilia. We will then focus on targeted immunotherapies for atopic disease, their effects on absolute peripheral eosinophil counts, and use of peripheral eosinophils as a predictor of treatment response. Recent Findings In atopic disease, lower absolute peripheral eosinophil counts are typically associated with improved outcomes. Much of the current evidence on eosinophils as a biomarker comes from post hoc analyses in therapeutic immunotherapy. While changes in eosinophilia were not the primary outcome of interest in many studies, some patterns did emerge. Cytolytic monoclonal antibodies AK002 and benralizumab completely reduce peripheral and tissue eosinophil numbers. Dupilumab may have paradoxical transient eosinophilia despite observed clinical efficacy. Summary Atopic inflammation is complex largely due to the various cytokines which affect eosinophil activation, proliferation, differentiation, and survival. This demonstrates the challenges of using peripheral eosinophilia alone as a biomarker for atopic disease activity. More attention should spotlight how different immunotherapy modalities affect eosinophil-driven responses.Keywords
This publication has 63 references indexed in Scilit:
- Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophiliaJournal of Blood Medicine, 2013
- High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effectsJournal of Allergy and Clinical Immunology, 2013
- Clinical and Immunologic Effects of Sublingual Immunotherapy on Patients with Allergic Rhinitis to House-Dust Mites: 1-Year follow-up ResultsAmerican Journal of Rhinology & Allergy, 2010
- Safety of a peanut oral immunotherapy protocol in children with peanut allergyJournal of Allergy and Clinical Immunology, 2009
- Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double‐blind, randomized, placebo‐controlled studyPediatric Allergy and Immunology, 2006
- Anti‐IL‐5 recombinant humanized monoclonal antibody (Mepolizumab) for the treatment of atopic dermatitisAllergy, 2005
- Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthmaJournal of Allergy and Clinical Immunology, 2001
- Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epitheliumClinical & Experimental Allergy, 2001
- Eosinophils in atopic dermatitisJournal of Allergy and Clinical Immunology, 1994
- Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavityJournal of Allergy and Clinical Immunology, 1991